Management of type II Diabetes Mellitus by Tonna, Antonella
No 6 Summer 2002    thechronic✱ill         2
• Avoiding symptoms of
hypoglycaemia and hyperglycaemia
• Maintaining patients as close to
euglycaemia as possible
• Slowing down of the progression of
chronic complications associated
with diabetes
• Normalisation of nutrition and
achievement of ideal body weight
• Maintaining  normal growth and
development in children
• Maintaining  a healthy, cheerful life
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There is currently no cure for diabetes mellitus (DM).
Irrespective of whether type I or type II diabetes is
treated, the overall goals of management and therapy
are targeted towards patient well being and may be
summarised as follows: 1,3
Maintaining euglycaemia
in a Type II diabetic
As discussed in Part 1 of the review,
the UK Prospective Diabetes Study
(UKPDS) has unequivocally shown that
tight glycaemic control has resulted in
less complications in type II diabetes.4
Based on these results, the American
Diabetes Association (ADA) has issued
goals of therapy for type II diabetes.
The ADA advocates that “the results of
the UKPDS mandate that treatment of
Type II diabetes includes aggressive
efforts to lower blood glucose levels to
as close to normal as possible.5”
In routine clinical practice a
glycosylated haemoglobin (HbA1c) less
than 8% should be acceptable (normal
range 3 - 8%).3
Diabetes care and
prevention of complications
It has been recognised that chronic
complications of diabetes are a major
cause of kidney disease, vision loss and
amputations in countries where
prevalence of the disease exceeds 5%.6
As a result, prevention of the onset has
become one of the major goals of
treatment. Consequently, European
countries (including Malta) have
collaborated to issue the “St. Vincent
Declaration” where recommendations
for the prevention of costly
complications have been put forward.7
These include a one third reduction in
blindness due to diabetes, a one third
reduction in people entering end stage
diabetic renal failure and reduction in
rate of limb amputations by one half.
Management of
Type II diabetes
a) Diet and exercise
Reduction in total body fat by 5%
may be associated with a significant
improvement in glycaemic control.2 In
addition, it improves efficacy of oral or
insulin treatment and helps in reducing
dyslipidaemia and cardiovascular risks.
A successful diet programme should be
tailored around a patient’s needs and
the advice of a nutritionist or dietician
should be sought. The pharmacist is in
an ideal position to offer advice
concerning:
• Special diabetic products: including
chocolates and biscuits - overall,
these should be avoided as they are
of limited benefit. Very often, such
products contain other sugars as an
alternative to glucose such as
sucrose, sorbitol and mannitol, that
offer no advantage to diabetics.
Besides, sorbitol in particular is
absorbed slowly from the intestine
and may produce osmotic
diarrhoea.8,10
• Sweeteners: non-nutritive
sweeteners such as aspartame
should be recommended.10
• Sugar content of liquid medicines
(both OTC and prescription).
Sweetening agents to be avoided
include fructose, syrup, honey and
glycerol.11
b)  Oral Hypoglycaemic Agents
The introduction of oral
hypoglycaemic agents (OHA’s) is
considered only after lifestyle
modifications have failed to reach
treatment goals after at least three
months. Drug therapy should not be
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instituted beforehand since this will
expose the patient to adverse effects
inappropriately.12  There are five classes
of OHA’s available that will be
discussed briefly:
i. Sulphonylureas: These act primarily
on the pancreas to increase the
amount of insulin secreted in
response to a given blood glucose
level.2  Consequently, a degree of
residual pancreatic function is
required. There is no evidence that
there is a difference in efficacy
between drugs in this class. The
major differences are in the half-life
(which relates to the hypoglycaemic
effect) and the site of metabolism
(i.e. whether renal or hepatic).12,13
Table I is a summary of the
characteristics of the sulphonylureas
available.
A number of factors may influence
the selection of a sulphonylurea:
• Patient’s age: an elderly patient is
at increased risk of hypoglycaemia.
Consequently, longer acting agents
(chlorpropamide in particular)
should be avoided. Hypoglycaemia is
a major concern with sulphonylureas
and if it persists for a number of
hours, the patient should be
referred for medical advice and
further treatment.2
• Patient’s body weight: since
sulphonylureas are associated with
an increased body weight, they
should be avoided in overweight
patients.12,13
• Patient’s general condition: an
inadequate food intake and
concurrent illness may increase the
risk of hypoglycaemia.2
• Concurrent medication: possible
drug interactions and their clinical
significance should be assessed.
Worth mentioning are salicylates as
these have an intrinsic
hypoglycaemic activity.13
• Renal and hepatic function: All
sulphonylureas should be avoided in
severe renal impairment except
tolbutamide, gliquidone and
gliclazide, which are hepatically
metabolised. They may be used if
there is no alternative therapy at
lower doses due to the increased
risk of hypoglycaemia.14 However,
many clinicians would prefer to
avoid all sulphonylureas when the
plasma creatinine concentration
exceeds 200-250µmol/l. The British
National Formulary recommends that
all sulphonylureas should possibly
be avoided in severe hepatic
impairment due to the increased
risk of hypoglycaemia and jaundice.
Lower doses are recommended if
there is no alternative.14
ii.  Biguanides: Metformin is the only
biguanide available in the UK and
has only been recently introduced in
the USA. Phenformin was previously
available but was withdrawn in the
1970’s due to the association with
fatal lactic acidosis.13 The
pharmacological actions of
metformin are numerous and
complex and proposed mechanisms
include decreased intestinal
absorption of glucose, increased
glucose uptake form the blood into
the tissues, decreased glucose
production in the liver and
decreased insulin requirements.16
The activity of the drug is therefore
dependent on residual pancreatic
activity. Metformin is the drug of
choice in obese type II DM since it
enhances weight loss.2,16 The
efficacy of metformin is considered
to be comparable to that of
sulphonylureas.13 The main
advantage of metformin is that it
does not produce hypoglycaemia
even when taken in overdosage.13,16
It does not undergo hepatic
metabolism and is eliminated
renally.16
Lactic acidosis is of major concern
with biguanide treatment since it is a
rare but fatal complication with a
30-50% fatality rate. The incidence of
lactic acidosis occurring with metformin
treatment is much less than that with
phenformin mainly because about 9%
of Caucasians exhibit a genetically
conferred hepatic defect of phenformin
hydroxylation. This does not apply to
metformin since it is not hepatically
metabolised. However, this is largely
preventable by a strict observance of
the contraindications, all of which are
conditions that predispose to
development or potentiation of lactic
acidosis. These include:
• acute illness (e.g. dehydration,
shock, heart failure) which results
in increased tissue lactate
production16
• renal impairment resulting in
accumulation of biguanide - in
practice metformin is usually
stopped when serum creatinine is in
the range of 150-160µmol/l2,16
• hepatic impairment where there is a
reduced lactate excretion16
• use of X-ray contrast media which
may predispose to acute renal
Table I: Pharmacokinetic Data of sulphonylureas2,3,13,15
Name Proprietary name Max daily dose (mg) Half life (hours) Dosing Frequency (in 24 hours)
Chlorporpamide Diabinese 500 35+ 1
Glibenclamide
(Glyburide) Daonil 15 4 - 13 1
Semidaonil
Euglucon
Gliclazide Diamicron 360 6 - 15 2
Glimepiride Amaryl 6 5 - 8 1
Glipizide Glibenese 20 3 1 - 2
Gliquidone Glurenorm 60 12 - 24 2 - 3
Tolbutamide Rastinon 2000 7 2 - 4
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efficacy these newer agents appear to
be much safer possibly because they
interact with a slightly different nuclear
receptor than troglitazone.2,21 The FDA
recommends intermittent monitoring of
liver function but does not specify at
what intervals. It is recommended to
repeat liver function tests every three
months. If the alanine aminotransferase
(ALT) is 1.5 times above the normal
value, this should be repeated within
one week. The drug should be stopped
if ALT levels are three times above
normal values.22
The National Institute of Clinical
Excellence (NICE) has issued guidelines
on both the use of rosiglitazone and
pioglitazone. NICE recommends that the
glitazones be used in combination with
metformin or sulphonylureas when the
combination of metformin/
sulphonylurea fails to lower glucose
levels within the range required. This
combination therapy may be introduced
before insulin is added on. In obese
patients, combining glitazone to
metformin is preferred over the
combination with sulphonylurea.23
iv.  Alpha glucosidase inhibitors:
Acarbose is the only available drug
in this group. Migitol is also
available in the USA but still not
available in Europe.22  Acarbose acts
on the brush border of the small
intestine where it competitively
binds to α−glucosidase enzymes
and inhibits absorption of starch
and sucrose. It has less effect on
lactose than on other
carbohydrates. This delayed
absorption results in a decrease in
post prandial glucose levels. Since
there is no effect on insulin
secretion, using the agent alone will
not result in hypoglycaemia. Overall
it is a very safe drug to use with a
mild adverse effect profile.22,24
Table II: Recommended Combination Therapy in Type 2 Diabetes Mellitus1
failure. It is therefore recommended
that metformin is stopped during
the 48 hours prior to and for 72
hours after the procedure, and
insulin used instead.2,14
Gastrointestinal upsets are a
common side effect of metformin
therapy but tolerance to this side effect
normally develops. It is therefore
recommended to start treatment at a
low dose and increase gradually until a
maximum dose of 3g daily is reached.2,14
iii. Thiazolidenediones: These drugs
include troglitazone, rosiglitazone,
pioglitazone and ciglitazone. Their
development is a major
breakthrough since they are able to
reduce insulin resistance (ie there is
an increased hypoglycaemic effect
with a lower level of insulin)
believed to be the initial defect in
the development of type II DM.17
The drugs act by binding to the
gamma isoform of peroxisome
proliferator-activated receptor
(PPAR) expressed predominantly in
adipose tissue. PPARs are
transcription factors that play an
important role in the regulation of
genes involved in insulin response.
This results in a reduced insulin
resistance resulting in lower levels
of insulin in circulation producing
the same glucose lowering
effect.2,17,18,19
Troglitazone was the first
thiazolidenedione to be launched - in
1997 in the USA and a year later in
Europe. It was withdrawn sometime
after, due to reports of fatal liver
failure. At least 90 cases were reported
in the USA with 70 resulting in death
or transplantation. Significant
elevations in liver enzymes occurred in
2.2% of patients.20,21  Pioglitazone and
rosiglitazone were launched in 2000.
Although there is no data comparing
v.  Repaglinide: This is a novel benzoic
acid derivative and is the only drug
available in its group. It is an
insulin secretagogue, which
stimulates the secretion of insulin
but only in the presence of glucose.
Consequently, when taken at meal
times, it lowers the post prandial
glucose concentration. It is given
on a ‘one meal, one tablet; no meal,
no tablet basis.’ 2,14
c) Stepwise treatment: With the
gradual and steady deterioration of
ß cell function over time, the
patient usually requires additional
therapy. After failure of
monotherapy, combining OHA’s is
the first choice. When control is not
achieved in this way, combining an
OHA to insulin may be considered
provided the patient still has some
residual pancreatic function. Insulin
is normally started as a night time
dose to suppress the hepatic output
with subsequent increase when
glycaemic control is not
achieved.2,22 Table II shows the
currently recommended/licensed
combinations of treatment.
d) Insulin: required when the secretion
of endogenous insulin is not
sufficient. The indications for
insulin treatment are as follows:
• non ketotic hyperosmolar coma
• pregnancy
• failure of oral treatment
• acute myocardial infarction
• during and after major surgery
• acute illness
• fasting blood glucose
> 17mmol/l 2
A detailed discussion of insulin
therapy will be presented in the third
and final part of this series. ✱
Monotherapy Sulphonylureas Metformin Glitazones Acarbose Repaglinid Insulin
Sulphonylureas b b b b r b
Metformin b b b b b b
Glitazones* r b b r r b
Acarbose b b b r r b
Repaglinide b r b r r r
Insulin b b b b b r
b=combination recommended or licensed;  r= combination not recommended.
*In the USA, licensed for use as monotherapy but may only be used in combination as per European license.
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